Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02788279 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 363
- Enrollment target
NCT02788279 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 363 participants.
The verdict
NCT02788279, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 363 participants
- Enrollment target
Study Summary
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study compares regorafenib, a standard of care therapy in this setting, to cobimetinib plus atezolizumab and atezolizumab monotherapy.
Interventions
- DRUG Regorafenib
- DRUG Cobimetinib
- DRUG Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2016-07-05 |
| Est. Completion | 2018-12-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02788279
The ClinicalTrials.gov registry entry for NCT02788279 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Regorafenib is the first listed.
NCT02788279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02788279 about?
NCT02788279 is a clinical study titled "A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)". This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study compares regorafenib, a standar...
What is the current status of trial NCT02788279?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 363 participants. The study started on 2016-07-05. Estimated completion is 2018-12-26.
What interventions are being tested in trial NCT02788279?
The interventions under investigation include: Regorafenib (DRUG), Cobimetinib (DRUG), Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody (DRUG).
Who is sponsoring clinical trial NCT02788279?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.